StockData
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. (BCAX) stock

BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.38−0.22 (-2.29%)

Close on Nov 18, 2026Market cap $620.70MP/E –Yield –

Bicara Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Bicara Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$162.75M. For fiscal 2025 it was -$107.11M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$107.11M–
FY2024Dec 31, 2024-$74.82M–
FY2023Dec 31, 2023-$46.21M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$56.79M–
Q2 FY2026Jun 30, 2026-$44.27M–
Q1 FY2026Mar 31, 2026-$37.57M–
Q4 FY2025Dec 31, 2025-$24.12M–
Q3 FY2025Sep 30, 2025-$29.29M–
Q2 FY2025Jun 30, 2025-$25.59M–
Q1 FY2025Mar 31, 2025-$28.11M–
Q4 FY2024Dec 31, 2024-$30.07M–
Q3 FY2024Sep 30, 2024-$17.23M–
Q2 FY2024Jun 30, 2024-$12.93M–
Q1 FY2024Mar 31, 2024-$14.59M–
Q4 FY2023Dec 31, 2023-$8.47M–

More Bicara Therapeutics figures

See a number that looks wrong?